The functions of PARP10 appear to be distinct than those of PARP1, and its catalytic activity is not affected by PARP1 inhibitors, which have been recently approved for treatment of breast and ovarian tumors with BRCA mutations [5, 6]. This evidence concerns the gene PARP1 and ovarian neoplasm.